Journal
ONCOTARGET
Volume 7, Issue 41, Pages 66491-66511Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.11582
Keywords
pancreatic cancer; sialic acid; galectin; epidermal growth factor receptor (EGFR); glycobiology
Categories
Funding
- NIH [R01CA112314, S10OD016374, P01HL107147]
- Willowcroft Foundation
Ask authors/readers for more resources
In prior work we reported that advanced stage, drug-resistant pancreatic cancer cells (the SW1990 line) can be sensitized to the EGFR-targeting tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib by treatment with 1,3,4-O-Bu(3)ManNAc (Bioorg. Med. Chem. Lett. (2015) 25(6): 1223-7). Here we provide mechanistic insights into how this compound inhibits EGFR activity and provides synergy with TKI drugs. First, we showed that the sialylation of the EGFR receptor was at most only modestly enhanced (by similar to 20 to 30%) compared to overall similar to 2-fold increase in cell surface levels of this sugar. Second, flux-driven sialylation did not alter EGFR dimerization as has been reported for cancer cell lines that experience increased sialylation due to spontaneous mutations. Instead, we present evidence that 1,3,4-O-Bu(3)ManNAc treatment weakens the galectin lattice, increases the internalization of EGFR, and shifts endosomal trafficking towards non-clathrin mediated (NCM) endocytosis. Finally, by evaluating downstream targets of EGFR signaling, we linked synergy between 1,3,4-O-Bu(3)ManNAc and existing TKI drugs to a shift from clathrin-coated endocytosis (which allows EGFR signaling to continue after internalization) towards NCM endocytosis, which targets internalized moieties for degradation and thereby rapidly diminishes signaling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available